Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 26, 2026, 5:30 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Combined regimen Clear all
Terminated Phase 1 Interventional

Study of Novel Regimens in Relapsed or Refractory Multiple Myeloma

NCT05289492
View directory record Official record
Conditions
Multiple Myeloma
Interventions
EOS884448, Iberdomide, Dexamethasone
Drug
Lead sponsor
iTeos Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
4
States / cities
Gilbert, Arizona • Norwich, Connecticut • Hackensack, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2024 · Synced Sep 26, 2026, 5:30 AM EDT
Recruiting Phase 1Phase 2 Interventional

Study of Combined Kidney and Blood Stem Cell Transplant From a Brother or Sister Donor

NCT03707262
View directory record Official record
Conditions
Renal Transplant Rejection, Tolerance, Kidney Transplant
Interventions
Donor CD34+ and CD3+ cells
Biological
Lead sponsor
Jeffrey Veale, MD
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Sep 26, 2026, 5:30 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Safety, Tolerability, and Efficacy of Immunomodulation With A Monoclonal Antibody Against CD40L in Combination With Transplanted Islet Cells in Adults With Brittle Type 1 Diabetes Mellitus (T1D)

NCT06305286
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Islet transplantation with Tegoprubart (AT-1501) immunosupression-based therapy
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 65 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Sep 26, 2026, 5:30 AM EDT
Terminated Phase 1 Interventional

Safety and Tolerability Study of Mivebresib Tablet Alone or in Combination With Ruxolitinib Tablet or Navitoclax Tablet in Adult Participants With Myelofibrosis

NCT04480086
View directory record Official record
Conditions
Myelofibrosis (MF)
Interventions
Mivebresib, Navitoclax, Ruxolitinib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
4
States / cities
Stony Brook, New York • Cincinnati, Ohio • Knoxville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2023 · Synced Sep 26, 2026, 5:30 AM EDT
Completed Not applicable Interventional Results available

Two Regimens of Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed Localized Ewing Sarcoma Family of Tumors

NCT00618813
View directory record Official record
Conditions
Ewing Sarcoma of Bone, Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
Interventions
radiation therapy, therapeutic conventional surgery, etoposide, ifosfamide, doxorubicin hydrochloride, cyclophosphamide, vincristine sulfate, topotecan hydrochloride, filgrastim
Other · Drug · Biological
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 30 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Monrovia, California
Source: ClinicalTrials.gov public record
Updated Sep 24, 2014 · Synced Sep 26, 2026, 5:30 AM EDT
Completed Phase 4 Interventional Results available

Drug and Talk Therapy for Fibromyalgia

NCT01038323
View directory record Official record
Conditions
Fibromyalgia
Interventions
CBT and milnacipran, CBT with a placebo, Educational with milnacipran
Other · Behavioral · Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 65 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 5, 2017 · Synced Sep 26, 2026, 5:30 AM EDT
Completed Phase 1 Interventional

Combination Chemotherapy in Treating Patients Who Have Advanced Solid Tumors

NCT00020488
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
FOLFIRI regimen, fluorouracil, irinotecan hydrochloride, leucovorin calcium
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 29, 2015 · Synced Sep 26, 2026, 5:30 AM EDT
Completed Phase 2 Interventional Results available

Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Therapy for Newly Diagnosed Multiple Myeloma

NCT02441686
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Bortezomib, Lenalidomide, Dexamethasone, Stem Cell Mobilization, Autologous Stem Cell Transplant
Drug · Procedure
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
8
States / cities
Denver, Colorado • Brewer, Maine • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Sep 26, 2026, 5:30 AM EDT
Completed Phase 3 Interventional Results available

Effects of Biktarvy on CFR in Stable HIV Patients

NCT03656783
View directory record Official record
Conditions
HIV
Interventions
Biktarvy
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 95 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 7, 2023 · Synced Sep 26, 2026, 5:30 AM EDT
Completed Phase 1 Interventional

Bioequivalence of Two NovoLog® Formulations in Subjects With Type 1 Diabetes

NCT01464099
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 1
Interventions
insulin aspart
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Oct 27, 2016 · Synced Sep 26, 2026, 5:30 AM EDT
Completed Phase 2 Interventional

In Situ, Autologous Therapeutic Vaccination Against Solid Cancers With Intratumoral Hiltonol®

NCT02423863
View directory record Official record
Conditions
Melanoma, Head and Neck Cancer, Sarcoma, Non-Melanoma Skin Cancers
Interventions
Hiltonol
Biological
Lead sponsor
Oncovir, Inc.
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
5
States / cities
Chevy Chase, Maryland • Easton, Maryland • Columbia, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2020 · Synced Sep 26, 2026, 5:30 AM EDT
Completed Phase 2 Interventional Results available

Combination Drug-Therapy for Patients With Untreated Obstructive Sleep Apnea

NCT04639193
View directory record Official record
Conditions
OSA, Obstructive Sleep Apnea
Interventions
Acetazolamide, Eszopiclone, Placebo, Venlafaxine
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated May 28, 2024 · Synced Sep 26, 2026, 5:30 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Safety and Activity of Digoxin With Decitabine in Adult AML and MDS

NCT03113071
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndromes
Interventions
Decitabine, Digoxin
Drug
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 15, 2021 · Synced Sep 26, 2026, 5:30 AM EDT
Active, not recruiting Phase 1 Interventional

Safety and Efficacy of Combination Osimertinib and Ipilimumab in Patients w EGFR Mutated NSCLC

NCT04141644
View directory record Official record
Conditions
Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor (Disorder)
Interventions
Ipilimumab, Osimertinib
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Sep 26, 2026, 5:30 AM EDT
Not yet recruiting Phase 1Phase 2 Interventional

DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers

NCT07707895
View directory record Official record
Conditions
Small Cell Lung Cancer, Large Cell Neuroendocrine Lung Carcinoma, Extrapulmonary Neuroendocrine Carcinoma of Small Cell Histology, Extrapulmonary Neuroendocrine Carcinoma of Large Cell Histology
Interventions
Obrixtamig, ZL-1310, Atezolizumab
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Tampa, Florida • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2026 · Synced Sep 26, 2026, 5:30 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens

NCT03412565
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Daratumumab, Bortezomib, Lenalidomide, Dexamethasone, Melphalan, Prednisone, Carfilzomib
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
265 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
16
States / cities
Southington, Connecticut • Jacksonville, Florida • Orlando, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Sep 26, 2026, 5:30 AM EDT
Recruiting Phase 3 Interventional

A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma

NCT06091865
View directory record Official record
Conditions
Diffuse Large B-cell Lymphoma (DLBCL)
Interventions
Odronextamab, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone/Prednisolone
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
904 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
23
States / cities
Scottsdale, Arizona • Los Angeles, California • Orange, California + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Sep 26, 2026, 5:30 AM EDT
Recruiting Phase 1Phase 2 Interventional

Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

NCT07288359
View directory record Official record
Conditions
Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, Metastatic Castration-resistant Prostate Cancer
Interventions
GVV858, Fulvestrant, Letrozole
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
3
States / cities
Atlanta, Georgia • Nashville, Tennessee • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Sep 26, 2026, 5:30 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)

NCT04240002
View directory record Official record
Conditions
Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia With FMS-like Tyrosine Kinase 3 (FLT3) Mutation / Internal Tandem Duplication (ITD)
Interventions
gilteritinib, fludarabine, cytarabine, granulocyte colony-stimulating factor (G-CSF)
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
6 Months to 21 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 4, 2026 · Synced Sep 26, 2026, 5:30 AM EDT
Recruiting Phase 1 Interventional

STARLITE for Unresectable High-Grade Gliomas

NCT06428045
View directory record Official record
Conditions
High Grade Glioma
Interventions
Magnetic Resonance (MR)-guided Laser Interstitial Thermal Therapy (LITT), Abacavir, Lamivudine, Ritonavir, Temozolomide, Focal Radiotherapy
Procedure · Drug · Radiation
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Sep 26, 2026, 5:30 AM EDT
Completed Phase 3 Interventional

Combination Chemotherapy With or Without Rituximab in Treating Patients With Newly Diagnosed Non-Hodgkin's Lymphoma

NCT00004112
View directory record Official record
Conditions
Lymphoma
Interventions
rituximab, CHOP regimen, cyclophosphamide, doxorubicin hydrochloride, prednisone, vincristine sulfate
Biological · Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2003
U.S. locations
2
States / cities
Los Angeles, California • Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 22, 2024 · Synced Sep 26, 2026, 5:30 AM EDT
Completed Phase 2 Interventional Results available

Vaccination Response in Tecfidera-Treated Versus Interferon-Treated Participants With Relapsing Forms of Multiple Sclerosis.

NCT02097849
View directory record Official record
Conditions
Relapsing Forms of Multiple Sclerosis
Interventions
dimethyl fumarate, tetanus diphtheria toxoids vaccine, 23-valent pneumococcal polysaccharide vaccine, meningococcal polysaccharide diphtheria conjugate vaccine (quadrivalent), non-pegylated interferon
Drug · Biological
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
14
States / cities
Gilbert, Arizona • Thornton, Colorado • Fort Lauderdale, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2017 · Synced Sep 26, 2026, 5:30 AM EDT
Active, not recruiting Not applicable Interventional

Comparison of Surgery and Medicine on the Impact of Diverticulitis (COSMID) Trial

NCT04095663
View directory record Official record
Conditions
Diverticulitis
Interventions
Partial Colectomy, Medical Management
Procedure · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
29
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 24 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Sep 26, 2026, 5:30 AM EDT
Recruiting Phase 2 Interventional

A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma

NCT04661137
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Selinexor 60 MG, Selinexor 80 MG, Selinexor 100 MG, Carfilzomib, Pomalidomide, Daratumumab, Dexamethasone
Drug
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 20, 2026 · Synced Sep 26, 2026, 5:30 AM EDT